REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regio...(compared with zero patients in the place...),Health

About Psoriasis

Psoriasis is a chronic, immune-mediated disorder, which results from inflammation in the skin and overproduction of skin cells that accumulate on the surface causing red, scaly plaques that may itch and bleed. This chronic inflammation is driven in part by tumor necrosis factor alpha, or TNF-alpha, a cytokine involved in the body's normal immune response. TNF-alpha is found at increased levels in psoriatic plaques and plays a crucial part in their formation and continued existence. It is estimated that 2 percent of the U.S. population has psoriasis, and about 30 percent of people with psoriasis have cases that are considered moderate to severe.

About REMICADE

REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is the only anti-TNF-alpha treatment approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE has demonstrated broad clinical utility in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 14 years and with more than one million patients treated worldwide through commercial experience.

In the U.S., REMICADE is approved for the following indications:

-- Reducing signs and symptoms, inhibiting the progression of structural

damage and improving physical function in patients with moderately to

severely active RA, when administered in combination with methotrexate.

-- Reducing signs and symptoms in patients with active AS.

-- Reducing signs and symptoms and inducing and maintaining clini
'/>"/>